Cai Jing Wang·2025-08-27 04:15Core Insights - The company reported a revenue growth of 48.64% to 1.168 billion yuan in the first half of 2025, with a net loss of 413 million yuan [1] - The core product, Toripalimab (brand name: Tuoyi®/LOQTORZI®, code: JS001), has received approval for 12 indications in mainland China and has been approved for sale in multiple regions including the US, EU, India, UK, Jordan, Australia, Singapore, UAE, and Kuwait [1] - The sales revenue from pharmaceuticals reached 1.059 billion yuan, marking a year-on-year increase of 49.41% [1] - Domestic market sales of Tuoyi® amounted to approximately 954 million yuan, reflecting a year-on-year growth of about 42% [1] - Toripalimab is recognized as the first domestically developed PD-1 monoclonal antibody successfully launched in China and the first innovative biologic drug developed and produced in China to be approved by the FDA, targeting various malignant tumors [1]